Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2026)

Revolution Medicines' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 400.92% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 400.92% YoY), while the FY2025 annual figure was $7.9 million, up 1247.86% from the prior year.
• Other Accumulated Expenses was $3.3 million for Q1 2026 at Revolution Medicines, down from $7.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $8.2 million in Q3 2025 to a low of $280000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $647000.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses slumped 85.04% in 2024, then surged 1247.86% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $505000.0 in 2022, then surged by 671.49% to $3.9 million in 2023, then plunged by 85.04% to $583000.0 in 2024, then soared by 1247.86% to $7.9 million in 2025, then slumped by 58.5% to $3.3 million in 2026.
• The last three Other Accumulated Expenses figures came in at $3.3 million (Q1 2026), $7.9 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.